Blueprint Medicines Corporation

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.

If you purchased Blueprint Medicines securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Blueprint Medicines securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On August 17, 2022, before trading hours, Blueprint Medicines announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) in patients with non-advanced systemic mastocytosis (SM). The results showed a deterioration in the absolute improvement in the symptom score from 15.6 points in this most recent trial versus 19.7 in Phase 1.

On this news, Blueprint Medicines’ share price fell $7.38 per share, or 10%, to close at $61.17 per share on August 17, 2022, on unusually heavy trading volume.

公司名称: Blueprint Medicines Corporation
股票代号: BPMC
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。